<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04439942</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0047</org_study_id>
    <nct_id>NCT04439942</nct_id>
  </id_info>
  <brief_title>4D-flow MRI to Assess Left Ventricular Obstruction in Hypertrophic Cardiomyopathy</brief_title>
  <acronym>HCMFLOW</acronym>
  <official_title>4D Flow Cardiac MRI Velocity Mapping in Patients With Hypertrophic Cardiomyopathy: Assessment of the Severity of the Left Ventricular Obstruction and Comparison With Echocardiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertrophic cardiomyopathy (HCM) is a frequent cardiac pathology with an estimated
      prevalence of 1/500 in France. The main risk factor for sudden death in this pathology is the
      presence and extent of left ventricular obstruction. To date, the only method allowing a
      reliable assessment of the extent of left ventricular obstruction is Doppler
      echocardiography. All patients with HCM should undergo cardiac magnetic resonance imaging
      (MRI) to confirm the diagnosis and for the detection of fibrosis, but conventional sequences
      cannot reliably assess the obstruction. 4D-flow MRI provides a complete coverage of an entire
      volume with the ability to simultaneously measure the outputs of all vessels within that
      volume in a single sequence and might be able to quantify left ventricular obstruction.

      The main objective of this study is to compare the quantification of left ventricular
      obstruction in hypertrophic cardiomyopathy by Doppler echocardiography and 4D flow MRI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Value of Correlation coefficient between the maximum gradient obtained by 4D flow MRI and the maximum gradient measured by echocardiography.</measure>
    <time_frame>day 1</time_frame>
    <description>Correlation coefficient assessment between the maximum gradient obtained by 4D flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Value of Correlation coefficient between the maximum gradient obtained by 4D flow MRI and the maximum gradient measured by phase-contrast</measure>
    <time_frame>day 1</time_frame>
    <description>Correlation coefficient assessment between the maximum gradient obtained by 4D flow MRI and the maximum gradient measured by phase-contrast</description>
  </secondary_outcome>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Obstruction</condition>
  <condition>Echocardiography</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cardiac magnetic resonance imaging (MRI)</intervention_name>
    <description>Cardiac MRI is a mandatory examination for Hypertrophic cardiomyopathy patients as it provides important information about the presence of fibrosis which is also directly associated with sudden cardiac death.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with Hypertrophic cardiomyopathy will undergo Doppler-echocardiography
        followed promptly (within the same hour) by a complete cardiac MRI with the addition of a
        4D Flow sequence (does not require the injection of a contrast agent and does not prolong
        the duration of the examination).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Presence of a Hypertrophic cardiomyopathy (HCM)

          -  Affiliation to a social security program

          -  Ability of the subject to understand and express opposition

        Exclusion Criteria:

          -  Major obesity (&gt; 140 kg) not allowing the patient to enter the tunnel of the machine
             whose diameter is less than 70cm,

          -  Age &lt; 18,

          -  Person under guardianship or curators,

          -  Pregnant woman,

          -  Allergy to gadolinium chelates,

          -  Claustrophobia,

          -  Any contraindications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cédric Renard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cédric Renard, MD</last_name>
    <phone>(33)3 22 08 75 37</phone>
    <email>renard.cedric@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yohann Bohbot, MD</last_name>
    <phone>(33)3 22 08 72 58</phone>
    <email>Bohbot.yohann@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jérémie VIAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Quentin DELPIERRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertrophic Cardiomyopathy</keyword>
  <keyword>4D-flow magnetic resonance imaging</keyword>
  <keyword>Obstruction</keyword>
  <keyword>maximal gradient</keyword>
  <keyword>echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

